RK-0080552
RK-0080552 (RK-552) is a NSD2 inhibitor with an IC50 of 0.11 μM, and it exhibits selectivity over histone methyltransferases G9a (IC50: 1.2 μM) and SET7/9 (IC50: >50 μM). RK-0080552 functionally inhibits NSD2 histone methyltransferase activity, reduces the dimethylation level of histone H3 lysine 36, suppresses IRF4 transcription, induces apoptosis and triggers cell death. RK-0080552 inhibits the growth of xenograft tumors and prolongs host survival. RK-0080552 is available for the research of multiple myeloma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 313527-11-6
- 分子式: C12H6N6O2
- 分子量:266.22
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Histone Methyltransferase アイソフォーム固有の製品をすべて表示
More
生物活性
|
NSD2 |
RK-0080552 (0-5 μM; 72 h) exerts significant, dose-dependent cytotoxicity in t (4;14)+ human multiple myeloma cell lines (KMS28-BM, KMS34, KMS26, NCI-H929, KMS11)[1].
RK-0080552 (0-5 μM; 1-3 days) reduces H3K36me2 levels and increases H3K27me3 levels in t (4;14)+ human multiple myeloma cell lines (KMS28-BM, KMS34, KMS26) in a dose- and time-dependent manner[1].
RK-0080552 (0-5 μM; 1-2 days) downregulates the expression of IRF4, a key growth and survival gene in multiple myeloma (MM)[1].
RK-0080552 (5 μM; 24 h) specifically induces apoptosis in primary t (4;14)+ human multiple myeloma CD138+ cells, with no effect on normal CD3+ T lymphocytes[1].
RK-0080552 (5 μM; 24 h) reduces global H3K36me2 levels and specifically decreases H3K36me2 enrichment at the IRF4 gene, particularly in intronic regions, in t (4;14)+ human multiple myeloma KMS34 cells[1].
RK-0080552 (0.5-4 μM; 24-72 h) exerts a synergistic cytotoxic effect with Pomalidomide (HY-10984) in t (4;14)+ human multiple myeloma cell lines (KMS28-BM, KMS34, KMS26, NCI-H929), and this effect correlates with enhanced downregulation of IRF4 expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:t(4;14)+ human multiple myeloma (MM) cell lines (KMS28-BM, KMS34, KMS26, NCI-H929, KMS11), t(4;14)- human MM cell lines (RPMI8226, KMM.1, SKMM1, JJN3, KMS21)
-
Concentration:0, 1, 2, 3, 4, 5 μM
-
Incubation Time:72 h
-
Result:Induced significant dose-dependent cytotoxicity in all tested t(4;14)+ MM cell lines.
Confirmed induction of cell death rather than cell cycle arrest in t(4;14)+ MM cell lines via flow cytometric analysis.
-
Cell Line:t(4;14)+ human MM cell lines (KMS28-BM, KMS34, KMS26)
-
Concentration:0, 3, 4, 5 μM
-
Incubation Time:24 h, 48 h
-
Result:Reduced IRF4 protein levels in a dose- and time-dependent manner in all tested t(4;14)+ MM cell lines.
| Species | Dose | Route | AUC | Cmax | T1/2 | Plasma Concentration |
|---|---|---|---|---|---|---|
| Mice[1] | 30 mg/kg | i.p. | 13.1 μM·h | 8.3 μM | 0.84 h | 7.12 μM |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID (male)[1]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:i.p.; 5 times a week; 3 weeks
-
Result:Suppressed subcutaneous KMS34 tumor growth.
Reduced tumor cell numbers, induced apoptosis, decreased H3K36me2 levels, and suppressed IRF4 expression in human CD138-expressing tumor cells.
Slightly prolonged overall survival of mice bearing intravenous KMS26 tumors.
化学情報
-
CAS 番号 313527-11-6
-
分子量 266.22
-
分子式 C12H6N6O2
-
SMILES
NC1=NON=C1C(N=N2)=NC3=C2C(C4=C3C=CC=C4)=O
-
別名
RK-552
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
RK-0080552 関連分類
HY-172614 関連分類
Powered by Bioz